SHR-3276 / Jiangsu Hengrui Pharma - LARVOL DELTA

SHR-3276-101: A Clinical Study of SHR-3276 for Injection in Patients With Advanced Malignant Tumors (clinicaltrials.gov) - P1/2 | N=115 | Recruiting | Sponsor: Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Not yet recruiting ➔ Recruiting

Enrollment open • Oncology • Solid Tumor

A Clinical Study of SHR-3276 for Injection in Patients With Advanced Malignant Tumors (clinicaltrials.gov) - P1/2 | N=115 | Not yet recruiting | Sponsor: Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Metastases • New P1/2 trial • Oncology • Solid Tumor

Suzhou Shengdia Biopharmaceutical Co., Ltd.’s drug application for clinical trial implicit license was accepted [Google translation] (jrj.com) - "On April 9, according to the official website of CDE, Suzhou Shengdia Biopharmaceutical Co., Ltd. jointly applied for the drug 'SHR-3276 injection' and received implicit permission for clinical trials, with the acceptance number CXSL2400081....Public information shows that the indications of the drug 'SHR-3276 Injection' are: advanced or metastatic solid tumors."

New trial • Oncology • Solid Tumor